LIMN
Liminatus Pharma Inc (LIMN)
Healthcare • NASDAQ • $5.16-8.35%
Key Fundamentals
- Symbol
- LIMN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $5.16
- Daily Change
- -8.35%
- Market Cap
- $9.40M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $4.12
- 52W Low
- $0.10
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- N/A
About Liminatus Pharma Inc
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Company websiteResearch LIMN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.